Health Care • Medical/Dental Instruments
$12.35 ▲ +0.22
(+1.81%)
MKT CAP: $519.4M • VOL: 476.2K
52W L $9 52W H $16
ANGO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-05-31 | FY 2024
FILED 2025-05-31 | FY 2023
FILED 2024-05-31 |
|---|---|---|---|
| Revenue (Total Sales) | $320.2M | $292.5M | $303.9M |
| YoY Revenue Growth % | +9.5% | -3.8% | — |
| Gross Profit | $174.9M | $157.7M | — |
| Gross Margin % | 54.6% | 53.9% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$39.9M | -$40.0M | -$192.4M |
| Operating Margin % | -12.5% | -13.7% | -63.3% |
| Net Income (GAAP) | -$36.7M | -$34.0M | -$184.3M |
| EBITDA (Normalized) | -$37.9M | -$36.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $3.1M | -$10.1M | -$28.2M |
| Capital Expenditures (CapEx) | $2.6M | $4.5M | — |
| Free Cash Flow (FCF) | $508.0K | -$14.6M | -$28.2M |
| FCF Margin % | 0.2% | -5.0% | -9.3% |
| Return on Invested Capital (ROIC %) | -23.4% | -23.8% | — |
| Cash & Short-Term Equivalents | $41.6M | $54.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $176.3M | $186.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ANGO.